drug_type
RELEVANT_DRUG
intervention_type
Vaccine
drug_description
Peptide cancer vaccine presenting the shared 36-amino-acid mutant calreticulin (CALR) C-terminal neoantigen to expand CALR-specific cytotoxic T cells targeting CALR-mutant malignant hematopoietic cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Peptide Vaccines
drug_category
PEPTIDE VACCINE
drug_class
Vaccine
drug_delivery_route
Not specified
drug_mechanism_of_action
Synthetic peptide vaccine comprising the shared 36-amino-acid mutant calreticulin (CALR) C-terminal neoantigen. After uptake by antigen-presenting cells, the peptide is presented on MHC to prime and expand CALR-mutant–specific cytotoxic T cells (and helper T cells), leading to recognition and killing of CALR-mutant malignant hematopoietic cells; adjuvants (e.g., poly-ICLC) enhance dendritic cell activation and antigen presentation.
drug_name
Mutant-CALR peptide vaccine
nct_id_drug_ref
NCT05025488